Trials / Completed
CompletedNCT00610714
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
A Phase II, Double-blind, Placebo-controlled, Multi-centre, Randomised Study of AZD0530 in Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 211 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD0530 | oral once daily dose |
| DRUG | Carboplatin | intravenous injection |
| DRUG | Paclitaxel | intravenous infusion |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2009-08-01
- Completion
- 2012-01-01
- First posted
- 2008-02-08
- Last updated
- 2012-12-18
- Results posted
- 2011-09-20
Locations
50 sites across 12 countries: Bulgaria, Canada, Denmark, France, Netherlands, Norway, Peru, Portugal, Romania, Russia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00610714. Inclusion in this directory is not an endorsement.